key: cord-0799881-vat6a6cd authors: Ortiz, Alberto title: Ckj consolidation among Q1 Urology and Nephrology journals date: 2020-10-09 journal: Clin Kidney J DOI: 10.1093/ckj/sfaa197 sha: 68b17332fee8423b5396d6a75d658aaecccca2f4 doc_id: 799881 cord_uid: vat6a6cd The Clinical Kidney Journal (ckj) impact factor from Clarivate’s Web of Science for 2019 was 3.388. This consolidates ckj among journals in the top 25% (first quartile, Q1) in the Urology and Nephrology field according to the journal impact factor. The manuscripts contributing the most to the impact factor focused on chronic kidney disease (CKD) epidemiology and evaluation, CKD complications and their management, cost-efficiency of renal replacement therapy, pathogenesis of CKD, familial kidney disease and the environment–genetics interface, onconephrology, technology, SGLT2 inhibitors and outcome prediction. We provide here an overview of the hottest and most impactful topics for 2017–19. major reference for renal replacement therapy epidemiology [2, 8, 28] . Furthermore, recent highly cited manuscripts have addressed the evaluation of CKD. This ranges from proposed age-dependent reference intervals for estimated and measured glomerular filtration rate [7] to novel urinary peptidomics biomarkers such as CKD273 that may allow an earlier diagnosis of CKD in the near future [5] . A further manuscript clarified the concept of CKD for wider audiences, in response to a New England Journal of Medicine clinical trial report in which 100% of participants appeared to have CKD, although in most of them it was G1/G2-without further evidence of kidney damage [31, 42, 43] . Additionally, ckj collaborated with the International Society of Nephrology by publishing its 0by25 initiative [zero preventable deaths from acute kidney injury (AKI) by 2025] manuscript focused on diagnosis of AKI in low-income countries [23] . Top-cited articles also included those related to CKD complications, such as cognitive function [6] and frailty [12] , as well as management of complications such as pain [4] and anaemia [32, 38] . Anaemia management focused on early clinical trials the novel drug family of oral hypoxia-inducible factor activators, such as daprodustat [32, 38] . Cost-efficiency focused on renal replacement therapy was another highly cited topic. The cost of public sector haemodialysis in India [11] , the relative cost of haemodialysis versus transplantation in Sweden [19] and the survival advantage afforded by dialysis and transplantation [14] were addressed. The pathogenesis of CKD was addressed from two different points of view. On one hand, the role of miRNA in immunoglobulin A (IgA) nephropathy was discussed [24] . We should remember that clinical trials of anti-miR, drugs targeting miRNAs and specifically miR21, are ongoing in another haematuric nephropathy (Alport syndrome [44] ). A second manuscript addressed capillary rarefaction, the pathogenic mechanism facilitating CKD progression through hypoxia that is activated very early in CKD and following AKI [17] . Familial nephropathies were well-represented among highly cited manuscripts. This likely reflects two ongoing revolutions: the arrival of the genomic era in the field of Nephrology, which is increasing the diagnosis of familial nephropathies even in patients not previously suspected to have a genetic kidney disease [45] , and the treatment revolution, in which the orphan disease policy favours the development of therapies for rare diseases, such as familial nephropathies. Topics addressed include genetic causes of focal segmental glomerulosclerosis in adults [20] , Bartter and Gitelman syndromes [18] and kidney diseases in porphyria [27] . A successful clinical trial of the RNAi therapeutic givosiran for acute intermittent porphyria was recently reported [46] . Kidney disease was one of the main themes in the trial, as givosiran may be associated with kidney disease deterioration despite improving porphyria symptoms. Therapy for familial nephropathy was also addressed, including evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome [3] , the state of the art of the management of autosomal-dominant polycystic kidney disease [22] and emerging targeted therapeutic strategies for autosomal-dominant polycystic kidney disease [16] . Some topics lie at the interface of genetic predisposition and environmental factors such as CKD of undetermined cause in Meso-America [13] , for which both a familial incidence and potential environmental factors have been suggested [47] , and congenital kidney and urinary tract anomalies [33] , for which both genetic and environmental causes have been characterized. Onconephrology was well-represented. One of the highest cited manuscripts addressed the kidney toxicity associated with pembrolizumab, a monoclonal antibody targeting the programmed cell death protein 1 receptor of lymphocytes, thereby enhancing the anti-tumour immune response and, potentially, autoimmunity [29] . An additional manuscript addressed the risk factors associated with post-kidney transplant malignancies [10] . A further study did not directly address onconephrology but rather the systemic impact on the kidney of intravitreal anti-vascular endothelial growth factor strategies, a local adaptation of drugs initially designed to be used systemically for cancer therapy [36] . Technology was also addressed in highly cited manuscripts. Both the impact of novel median cutoff dialysers [15] and the relative role of extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy as first-line approach to renal calculi [21] were reported. SGLT2 inhibitors may be the most significant advance in kidney protection and treatment of CKD and its cardiovascular complications in 30 years [48] . Highly cited SGLT2 manuscripts dealt with the results of the CREDENCE trial of canagliflozin for diabetic kidney disease as compared with the impact of atrasentan in another highly publicized trial [30] , as well as with the rationale for EMPA-KIDNEY, a clinical trial that will address the efficacy of empagliflozin in non-diabetic CKD [9] . A further manuscript addressed the benefits of SGLT2 inhibitors beyond glucose control [41] . Finally, a further set of highly cited studies focussed on outcome prediction in different kidney disease contexts. One study focused on causes and predictors of mortality in biopsy-proven lupus nephritis [25] . The different patterns of progression of later stages of CKD were also characterized [26] , as well as the relationship between obesity, the new adipokine C1q/tumour necrosis factor-related protein-1 and CKD progression [35] . Use of machine-learning algorithms was explored to predict poor outcomes in hypertensive patients based on blood pressure variability [37] . Another text studied the usefulness of antiphospholipase 2 receptor levels to predict complete spontaneous remission in untreated membranous nephropathy, and thus to help in initial decision-making regarding initiation of immunosuppressive therapy [39] . The last highly cited manuscript assessed whether the presence of active tubulointerstitial nephritis in non-scarred renal cortex improved prediction of renal outcomes in IgA nephropathy [40] . The new Clinical Kidney Journal, 4 years later The European Renal Association -European Dialysis and Transplant Association registry annual report 2014: a summary Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome update on pain management in patients with chronic kidney disease Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease Cognitive function and advanced kidney disease: longitudinal trends and impact on decisionmaking Age-dependent reference intervals for estimated and measured glomerular filtration rate The European Renal Association -European Dialysis and Transplant Association (ERA-EDTA) registry annual report 2015: a summary The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network Cost of hemodialysis in a public sector tertiary hospital of India Frailty and chronic kidney disease: current evidence and continuing uncertainties What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis A comparative analysis of survival of patients on dialysis and after kidney transplantation Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease Capillary rarefaction from the kidney point of view Clinical and diagnostic features of Bartter and Gitelman syndromes Do kidney transplantations save money? A study using a before-after design and multiple register-based data from Sweden Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults Extracorporeal shock wave lithotripsy versus flexible ureterorenoscopy in the treatment of untreated renal calculi Management of autosomal-dominant polycystic kidney disease-state-of-the-art International Society of Nephrology's 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries MicroRNAs: a new avenue to understand, investigate and treat immunoglobulin A nephropathy? Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience Patterns of progression of chronic kidney disease at later stages Porphyria and kidney diseases The European Renal Association -European Dialysis and Transplant Association (ERA-EDTA) registry annual report 2016: a summary Renal toxicities associated with pembrolizumab Canagliflozin and renal events in diabetes with established nephropathy clinical evaluation and study of diabetic nephropathy with atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clarifying the concept of chronic kidney disease for nonnephrologists Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis Developmental pathology of congenital kidney and urinary tract anomalies Air pollution and kidney disease: review of current evidence Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1 Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension Use of machine-learning algorithms to determine features of systolic blood pressure variability that predict poor outcomes in hypertensive patients Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy Assessment of active tubulointerstitial nephritis in non-scarred renal cortex improves prediction of renal outcomes in patients with IgA nephropathy Sodium-glucose cotransporter inhibitors: beyond glycaemic control Cardiovascular safety of febuxostat Cardiovascular safety of febuxostat or allopurinol in patients with gout Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways Diagnostic utility of exome sequencing for kidney disease. Reply Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria Meso-American nephropathy: what we have learned about the potential genetic influence on chronic kidney disease development SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA A.O. is ckj Editor-in-Chief.